Takeaway

• Tamoxifen recipients show better quality of life (QoL) than aromatase inhibitor (AI) recipients in functioning (several areas), pain and emotional areas, according to a prospective cohort study of postmenopausal patients with early-stage breast cancer in the journal Menopause .

Why this matters

• Findings should help clinicians and patients decide ...